Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA v. HHS

Executive Summary

D.C. federal court will hear additional arguments on the Pharmaceutical Research & Manufacturers of America's challenge of HHS' approval of the Michigan Medicaid supplemental rebate program Jan. 24. The court wants information on the effect the non-Medicaid aspects of the program will have on Medicaid beneficiaries. During oral arguments Jan. 6, the Department of Justice said the court should defer to HHS' approval (1"The Pink Sheet" Sept. 2, p. 6)...

You may also be interested in...



Michigan Rx Rebate Program Decision Should Be Left To HHS, DoJ Tells Court

HHS' approval of the Michigan Medicaid supplemental rebate program should be given deference in the Washington, D.C. federal court's review of the program, the Department of Justice said during oral arguments Aug. 28

Stalemate Over Virtual Audits In EU As Commission Tells TEAM-NB To Back Off

Notified bodies’ efforts to enhance a harmonized approach to remote audits have failed, raising questions about whether there is any avenue left to get vital devices certified by the 26 May EU MDR deadline.

Amneal’s Generics Business Reinvigorated By New Launches

As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel